Novo Nordisk A/S

At Novo Nordisk, we are driving change to defeat diabetes and otherserious chronic diseases. Novo Nordisk is a global healthcare company with more than 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic diseases: haemophilia, growth disordersand obesity.
Headquartered in Denmark, Novo Nordisk employs approximately 43,200 people in 80 countries andmarkets its products in more than 170 countries.

In the initial EBiSC phase, Novo Nordisk contributed to proof-of-concept studies and ensured valuable connections to IMI's stem cell project StemBANCC. In EBiSC2, Novo Nordisk is co-leading the Upscaling of iPSC workflows and contributes to developing up-scaling and automation technologies for culturing hiPSC as well as pancreatic cells derived from hiPSCs.

More information: www.novonordisk.com »